Last reviewed · How we verify
NCT03796845: exercise
Limited Versus No-limited Shoulder Movement in Breast Cancer Surgery
NA trial testing No limited movement after surgery in Breast Neoplasms in 465 participants. Completed in 20 December 2019.
1 July 2019
Quick facts
| Lead sponsor | Instituto Nacional de Cancer, Brazil |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 465 |
| Start date | 1 February 2019 |
| Primary completion | 1 July 2019 |
| Estimated completion | 20 December 2019 |
| Sites | 1 location across Brazil |
Drugs / interventions tested
- No limited movement after surgery
Conditions studied
- Breast Neoplasms — all drugs for Breast Neoplasms →
Sponsor
Instituto Nacional de Cancer, Brazil — full company profile →
Who can join
Adults 18 to 80, female only, with Breast Neoplasms. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Randomized clinical trial that will include women aged 18 or older, submitted a curative surgery for breast cancer at Hospital do Câncer III (HCIII-INCA). Patients will be allocated into two groups: Intervention (upper limbs no-limited movement with amplitude above 90º for flexion and abduction of shoulder) and Control (upper limbs limited movement at maximum 90º amplitude flexion and abduction of shoulder, until withdrawal surgical points). Sociodemographic and clinical data will be collected through interviews, questionnaires and electronic and physical records. The outcomes will be incidence of operative wound complications, like edema, joint restraint, winged scapula, pain, axillary web syndrome through the physical examination, performed by the nursing and physiotherapy team throughout the intervention period, ending in the 30-day post-operatory.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Shoulder amplitude movement does not influence postoperative wound complications after breast cancer surgery: a randomized clinical trial.
Teodózio CGC, Marchito LO, Fabro EAN, Macedo FO, et al · · 2020 · cited 5× · PMID 32804282 · DOI 10.1007/s10549-020-05826-9
Verify or expand the search:
- PubMed search for NCT03796845
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Neoplasms
Currently open trials in the same condition.
- NCT07214532 — Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer · NA · recruiting
- NCT07500428 — Construction of a Benchmark for Breast Ultrasound AI Interpretation and Performance Evaluation of Multimodal AI Models · recruiting
- NCT07581834 — Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multic · Phase 2 · recruiting
- NCT07222215 — PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA) · Phase 2 · recruiting
- NCT07465393 — Facility-Based Multi-Modal Rehab vs. Home-Based Resistance Exercise for Quality of Life in Breast Cancer Survivors · NA · recruiting
Other Instituto Nacional de Cancer, Brazil trials
Trials by the same sponsor.
- NCT06708702 — Copaíba-based Mouthwash in Oral Mucotitis Prevention and Treatment in Oral Cancer Patients During Radioteraphy · Phase 2 · withdrawn
- NCT06299462 — PTCy and ATG for MSD and MUD Transplants · Phase 1, PHASE2 · recruiting
- NCT06071637 — Low Power Laser Therapy As Prevention Of Oral Mucositis And Oropharyngeal Pain In Patients Undergoing Allogenetic HSCT · Phase 3 · recruiting
- NCT05535452 — Photobiomodulation for Prevention of Radiodermatitis in Women With Breast Cancer Undergoing Adjuvant Radiotherapy · NA · unknown
- NCT06217224 — Evaluation of Prophylactic Photobiomodulation Therapy in Patients With Osteosarcoma · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03796845 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Instituto Nacional de Cancer, Brazil
- Last refreshed: 7 April 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03796845.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing